Clinical Effectiveness of Preoperative 18F-FDG PET/CT in Predicting Pathological Tumor Grade in Patients with Pseudomyxoma Peritonei Originating from Appendix: A Retrospective Cohort Study

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Dec 11

PMID 38082170

Authors

Kenta Aso

Yoshimasa Gohda

Masatoshi Hotta

Ryogo Minamimoto

Yosuke Shimizu

Yukari Uemura

Hideaki Yano

Affiliations

Soon will be listed here.

Abstract

Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the standard treatment for patients with pseudomyxoma peritonei (PMP). In some malignancies, the standard uptake value of positron emission tomography with 2-deoxy-2-18F-fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) is now accepted as a reliable indicator of neoplastic behavior. This study aimed to evaluate the association between the maximum standardized uptake value (SUVmax) and pathological grade in patients with PMP and to investigate the significance of SUVmax in the preoperative assessment of these patients.

Patients And Methods: In this retrospective single-center study, consecutively enrolled patients diagnosed with PMP of appendiceal origin underwent preoperative 18F-FDG PET/CT. SUVmax was calculated as the highest SUVmax value in the abdomen excluding the primary site. SUVmax was compared with the pathological grade (low or high grade) of PMP tumors according to the World Health Organization classification and further analyzed with respect to the estimated cutoff point, sensitivity, specificity, and receiver operating characteristic.

Results: In total, 160 patients were included. CRS was successfully performed in 93 patients and palliative debulking surgery in 67 patients. The pathological grade was high in 45 patients and low in 115. High-grade patients had a higher median SUVmax on 18F-FDG PET/CT than did low-grade patients (3.83 versus 2.34, p < 0.001). The highest area under the curve was 0.81, with a sensitivity of 77.8%, specificity of 72.3%, and cutoff point of 2.63.

Conclusion: This study suggests that the SUVmax of preoperative 18F-FDG PET/CT is associated with the pathological grade in patients with PMP.

Citing Articles

Imaging of Peritoneal Surface Malignancies.

Caruso D, Sammartino P, Polici M, Masci G, Biacchi D, Zerunian M J Surg Oncol. 2024; 130(6):1203-1212.

PMID: 39508563 PMC: 11826024. DOI: 10.1002/jso.27979.

Comparative Analysis of Volatile Components in Chi-Nan and Ordinary Agarwood Aromatherapies: Implications for Sleep Improvement.

Jiang Z, Mou J, Feng J, Zhang S, Li D, Liu Y Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338358 PMC: 11435107. DOI: 10.3390/ph17091196.

Prognostic evaluation in gallbladder carcinoma: Introducing a composite risk model integrating nutritional and immune markers.

Yang S, Zou R, Dai Y, Hu H, Li F Biomol Biomed. 2024; 25(2):425-435.

PMID: 39067064 PMC: 11734823. DOI: 10.17305/bb.2024.10673.

References

Panarelli N, Yantiss R . Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011; 135(10):1261-8. DOI: 10.5858/arpa.2011-0034-RA. View

Smeenk R, van Velthuysen M, Verwaal V, Zoetmulder F . Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2007; 34(2):196-201. DOI: 10.1016/j.ejso.2007.04.002. View

Sugarbaker P, Schellinx M, Chang D, Koslowe P, von Meyerfeldt M . Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996; 20(5):585-91; discussion 592. DOI: 10.1007/s002689900091. View

Lin Y, Xu D, Li X, Yan F, Xu H, Peng Z . Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines. Orphanet J Rare Dis. 2021; 16(1):85. PMC: 7881689. DOI: 10.1186/s13023-021-01723-6. View

Govaerts K, Lurvink R, de Hingh I, Van der Speeten K, Villeneuve L, Kusamura S . Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2020; 47(1):11-35. DOI: 10.1016/j.ejso.2020.02.012. View

Ronnett B, Zahn C, Kurman R, Kass M, Sugarbaker P, Shmookler B . Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol. 1995; 19(12):1390-408. DOI: 10.1097/00000478-199512000-00006. View

Carr N, Cecil T, Mohamed F, Sobin L, Sugarbaker P, Gonzalez-Moreno S . A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2015; 40(1):14-26. DOI: 10.1097/PAS.0000000000000535. View

Gonzalez-Moreno S, Sugarbaker P . Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004; 91(3):304-11. DOI: 10.1002/bjs.4393. View

Sugarbaker P . Peritonectomy procedures. Ann Surg. 1995; 221(1):29-42. PMC: 1234492. DOI: 10.1097/00000658-199501000-00004. View

10.

Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F . Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol. 2009; 36(3):315-23. DOI: 10.1016/j.ejso.2009.09.001. View

11.

Hotta M, Minamimoto R, Gohda Y, Igari T, Yano H . Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei. Eur Radiol. 2019; 29(10):5709-5716. DOI: 10.1007/s00330-019-06102-1. View

12.

Dubreuil J, Giammarile F, Rousset P, Bakrin N, Passot G, Isaac S . FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. Eur J Nucl Med Mol Imaging. 2016; 43(9):1630-7. DOI: 10.1007/s00259-016-3347-z. View

13.

Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M . Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci. 2017; 79(4):527-543. PMC: 5719212. DOI: 10.18999/nagjms.79.4.527. View

14.

Bakheet S, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J . F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med. 2000; 25(2):100-3. DOI: 10.1097/00003072-200002000-00003. View

15.

Hustinx R, Smith R, Benard F, Rosenthal D, Machtay M, FARBER L . Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999; 26(10):1345-8. DOI: 10.1007/s002590050593. View

16.

Shreve P . Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998; 25(3):259-64. DOI: 10.1007/s002590050226. View

17.

Shreve P, Anzai Y, Wahl R . Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999; 19(1):61-77; quiz 150-1. DOI: 10.1148/radiographics.19.1.g99ja0761. View

18.

Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S . FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med. 1996; 10(2):185-91. DOI: 10.1007/BF03165391. View